{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T23:44:57Z","timestamp":1789083897972,"version":"build-2803163510"},"reference-count":103,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2023,4,29]],"date-time":"2023-04-29T00:00:00Z","timestamp":1682726400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000272","name":"NIHR","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,9,19]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Recent advances in atopic dermatitis (AD) present the condition as a heterogeneous disease of distinct endotypes across ethnic groups. AD in people with skin of colour may appear psoriasiform, lichenoid, scaly or papular, with a violaceous colour and there is a higher prevalence of post-inflammatory dyspigmentation compared with affected individuals of White ethnicity. These differences in clinical presentation may limit the use of AD assessment tools in people with skin of colour, leading to the potential for misdiagnosis and underestimation of severity, particularly in relation to assessment of erythema. Recent targeted therapies for AD have been studied in multiple ethnic groups; however, ethnicity-based subgroup analysis is often not performed. Further research is required to understand whether treatment responses or safety may differ among ethnic groups.<\/jats:p>","DOI":"10.1093\/ced\/llad162","type":"journal-article","created":{"date-parts":[[2023,4,29]],"date-time":"2023-04-29T13:11:40Z","timestamp":1682773900000},"page":"1091-1101","source":"Crossref","is-referenced-by-count":21,"title":["Atopic dermatitis in skin of colour. Part 2: considerations in clinical presentation and treatment options"],"prefix":"10.1093","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2346-6773","authenticated-orcid":false,"given":"Christian","family":"Gan","sequence":"first","affiliation":[{"name":"Department of Dermatology, The Royal Children\u2019s Hospital , Melbourne, VIC , Australia"},{"name":"Department of Dermatology, St Vincent\u2019s Hospital , Melbourne, VIC , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4692-3794","authenticated-orcid":false,"given":"Satveer","family":"Mahil","sequence":"additional","affiliation":[{"name":"St John\u2019s Institute of Dermatology, Guy\u2019s and St Thomas NHS Foundation Trust and King\u2019s College London , London , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5151-5539","authenticated-orcid":false,"given":"Andrew","family":"Pink","sequence":"additional","affiliation":[{"name":"St John\u2019s Institute of Dermatology, Guy\u2019s and St Thomas NHS Foundation Trust and King\u2019s College London , London , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9747-1882","authenticated-orcid":false,"given":"Michelle","family":"Rodrigues","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The Royal Children\u2019s Hospital , Melbourne, VIC , Australia"},{"name":"Department of Paediatrics, The University of Melbourne , Parkville, VIC , Australia"},{"name":"Chroma Dermatology, Pigment and Skin of Colour Centre , VIC , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,4,29]]},"reference":[{"key":"2023112112581886300_llad162-B1","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1111\/bjd.17608","article-title":"Under-representation of skin of colour in dermatology images: not just an educational issue","volume":"180","author":"Lester","year":"2019","journal-title":"Br J Dermatol"},{"key":"2023112112581886300_llad162-B2","first-page":"124","article-title":"Dermatology education in skin of colour: where we are and where do we go?","volume":"12","author":"Onasanya","year":"2021","journal-title":"Can Med Educ J"},{"key":"2023112112581886300_llad162-B3","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.jaad.2005.10.068","article-title":"Disparities in dermatology educational resources","volume":"55","author":"Ebede","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"2023112112581886300_llad162-B4","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1016\/j.jaci.2015.08.015","article-title":"The Asian atopic dermatitis phenotype combines features of atopic dermatitis and psoriasis with increased TH17 polarization","volume":"136","author":"Noda","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"2023112112581886300_llad162-B5","first-page":"118","article-title":"Atypical manifestations of atopic dermatitis","volume":"3","author":"Gulati","year":"2021","journal-title":"J Skin Sex Transm Dis"},{"key":"2023112112581886300_llad162-B6","doi-asserted-by":"crossref","first-page":"471","DOI":"10.4103\/0019-5154.87112","article-title":"Epidemiology and clinical features of atopic dermatitis in India","volume":"56","author":"Kanwar","year":"2011","journal-title":"Indian J Dermatol"},{"key":"2023112112581886300_llad162-B7","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/exd.13514","article-title":"Atopic dermatitis in diverse racial and ethnic groups \u2013 variations in epidemiology, genetics, clinical presentation and treatment","volume":"27","author":"Kaufman","year":"2018","journal-title":"Exp Dermatol"},{"issue":"3 Suppl, 1","key":"2023112112581886300_llad162-B8","first-page":"S20","article-title":"Dermatological conditions in skin of color: managing atopic dermatitis","volume":"14","author":"Sangha","year":"2021","journal-title":"J Cosmet Dermatol"},{"key":"2023112112581886300_llad162-B9","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1111\/bjd.15271","article-title":"A comparison study of clinician-rated atopic dermatitis outcome measures for intermediate- to dark-skinned patients","volume":"176","author":"Zhao","year":"2017","journal-title":"Br J Dermatol"},{"key":"2023112112581886300_llad162-B10","doi-asserted-by":"crossref","first-page":"281","DOI":"10.4103\/ijpd.IJPD_52_17","article-title":"The clinico-epidemiological profile of atopic dermatitis in residential schoolchildren: a study from South Chhattisgarh, India","volume":"18","author":"Upendra","year":"2017","journal-title":"Indian J Paediatr Dermatol"},{"key":"2023112112581886300_llad162-B11","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/j.1525-1470.2012.01740.x","article-title":"Atopic dermatitis in African American children: addressing unmet needs of a common disease","volume":"29","author":"Vachiramon","year":"2012","journal-title":"Pediatr Dermatol"},{"key":"2023112112581886300_llad162-B12","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1111\/j.1365-4632.2004.02360.x","article-title":"Current epidemiology of atopic dermatitis in south-eastern Nigeria","volume":"43","author":"Nnoruka","year":"2004","journal-title":"Int J Dermatol"},{"key":"2023112112581886300_llad162-B13","doi-asserted-by":"crossref","first-page":"504","DOI":"10.4103\/0378-6323.69066","article-title":"Atopic dermatitis in infants and children in India","volume":"76","author":"Dhar","year":"2010","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"2023112112581886300_llad162-B14","doi-asserted-by":"crossref","first-page":"317","DOI":"10.4103\/cmi.cmi_81_20","article-title":"Atopic dermatitis in children: an update for pediatricians","volume":"18","author":"Sathishkumar","year":"2020","journal-title":"Curr Med Issues"},{"key":"2023112112581886300_llad162-B15","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.jaad.2007.03.033","article-title":"Lichenoid and other clinical presentations of atopic dermatitis in an inner city practice","volume":"58","author":"Allen","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"2023112112581886300_llad162-B16","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1046\/j.1365-2133.2002.04965.x","article-title":"Reliance on erythema scores may mask severe atopic dermatitis in black children compared with their white counterparts","volume":"147","author":"Ben-Gashir","year":"2002","journal-title":"Br J Dermatol"},{"key":"2023112112581886300_llad162-B17","volume-title":"Dupilumab for Treating Moderate to Severe Atopic Dermatitis. Technology Appraisal Guidance","author":"National Institute for Health and Care Excellence","year":"2018"},{"key":"2023112112581886300_llad162-B18","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.jaad.2018.04.047","article-title":"Ethnic differences and comorbidities of 909 prurigo nodularis patients","volume":"79","author":"Boozalis","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"2023112112581886300_llad162-B19","author":"Givler","year":"2022","journal-title":"Pityriasis Alba"},{"key":"2023112112581886300_llad162-B20","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1001\/archderm.1952.01530300068007","article-title":"Lichen simplex chronicus in orientals","volume":"66","author":"Rein","year":"1952","journal-title":"AMA Arch Dermat Syphilol"},{"key":"2023112112581886300_llad162-B21","doi-asserted-by":"crossref","first-page":"86","DOI":"10.4103\/jdds.jdds_20_19","article-title":"Labial melanotic macules in atopic dermatitis: an observational study","volume":"23","author":"Aljasser","year":"2019","journal-title":"J Dermatol Dermatol Surg"},{"key":"2023112112581886300_llad162-B22","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1111\/ijd.14010","article-title":"Atopic labial pigmentation: a new diagnostic feature in Asian patients with atopic dermatitis","volume":"57","author":"Kang","year":"2018","journal-title":"Int J Dermatol"},{"key":"2023112112581886300_llad162-B23","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1001\/jama.2020.4006","article-title":"Pathophysiology, clinical presentation, and treatment of psoriasis: a review","volume":"323","author":"Armstrong","year":"2020","journal-title":"JAMA"},{"key":"2023112112581886300_llad162-B24","first-page":"16","article-title":"Psoriasis in skin of color: epidemiology, genetics, clinical presentation, and treatment nuances","volume":"7","author":"Alexis","year":"2014","journal-title":"J Clin Aesth Dermatol"},{"key":"2023112112581886300_llad162-B25","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.clindermatol.2015.09.006","article-title":"Lichen planus and other lichenoid dermatoses: kids are not just little people","volume":"33","author":"Payette","year":"2015","journal-title":"Clin Dermatol"},{"key":"2023112112581886300_llad162-B26","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.jaad.2018.02.010","article-title":"Lichen planus and lichenoid dermatoses: clinical overview and molecular basis","volume":"79","author":"Tziotzios","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"2023112112581886300_llad162-B27","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1001\/jamadermatol.2020.3260","article-title":"Efficacy and safety of baricitinib combined with topical corticosteroids for treatment of moderate to severe atopic dermatitis: a randomized clinical trial","volume":"156","author":"Reich","year":"2020","journal-title":"JAMA Dermatol"},{"key":"2023112112581886300_llad162-B28","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s40257-021-00586-8","article-title":"Eczematous drug eruptions","volume":"22","author":"Blum","year":"2021","journal-title":"Am J Clin Dermatol"},{"key":"2023112112581886300_llad162-B29","doi-asserted-by":"crossref","first-page":"191","DOI":"10.3109\/1040841X.2011.645520","article-title":"Cutaneous id reactions: a comprehensive review of clinical manifestations, epidemiology, etiology, and management","volume":"38","author":"Ilkit","year":"2012","journal-title":"Crit Rev Microbiol"},{"key":"2023112112581886300_llad162-B30","first-page":"749","article-title":"Mycology \u2013 an update part 2: dermatomycoses: clinical picture and diagnostics","volume":"12","author":"Nenoff","year":"2014","journal-title":"J Dtsch Dermatol Ges"},{"key":"2023112112581886300_llad162-B31","first-page":"99","article-title":"Factors leading to dermatophytosis","volume":"59","author":"Qadim","year":"2013","journal-title":"Ann Parasitol"},{"key":"2023112112581886300_llad162-B32","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1159\/000495290","article-title":"A review of scabies: an infestation more than skin deep","volume":"235","author":"Chandler","year":"2019","journal-title":"Dermatology"},{"key":"2023112112581886300_llad162-B33","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/s13555-019-00325-2","article-title":"Review of scabies in the elderly","volume":"9","author":"Raffi","year":"2019","journal-title":"Dermatol Ther (Heidelb)"},{"key":"2023112112581886300_llad162-B34","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1258\/ijsa.2010.010243","article-title":"Secondary syphilis: the classical triad of skin rash, mucosal ulceration and lymphadenopathy","volume":"21","author":"Mullooly","year":"2010","journal-title":"Int J STD AIDS"},{"key":"2023112112581886300_llad162-B35","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/B978-141602613-6.10039-4","volume-title":"The Travel and Tropical Medicine Manual","author":"Baeten","year":"2008","edition":"4th edn"},{"key":"2023112112581886300_llad162-B36","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/j.1365-4362.1987.tb00532.x","article-title":"Clinical manifestations of secondary syphilis","volume":"26","author":"Hira","year":"1987","journal-title":"Int J Dermatol"},{"key":"2023112112581886300_llad162-B37","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1159\/000514581","article-title":"Bidirectional association between psoriasis and atopic dermatitis: a nationwide population-based cohort study","volume":"237","author":"Dai","year":"2021","journal-title":"Dermatology"},{"key":"2023112112581886300_llad162-B38","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s11882-013-0343-2","article-title":"Racial differences in allergic sensitization: recent findings and future directions","volume":"13","author":"Wegienka","year":"2013","journal-title":"Curr Allergy Asthma Rep"},{"key":"2023112112581886300_llad162-B39","doi-asserted-by":"crossref","first-page":"11175","DOI":"10.1038\/s41598-021-90105-w","article-title":"Transcriptomic analysis of atopic dermatitis in African Americans is characterized by Th2\/Th17-centered cutaneous immune activation","volume":"11","author":"Wongvibulsin","year":"2021","journal-title":"Sci Rep"},{"key":"2023112112581886300_llad162-B40","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.jaad.2013.10.010","article-title":"Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis","volume":"70","author":"Eichenfield","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"2023112112581886300_llad162-B41","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1111\/bjd.20660","article-title":"Why we should abandon the misused descriptor \u2018erythema\u2019","volume":"185","author":"Finlay","year":"2021","journal-title":"Br J Dermatol"},{"key":"2023112112581886300_llad162-B42","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/DER.0000000000000895","article-title":"The Eczema Area and Severity Index \u2013 a practical guide","volume":"33","author":"Hanifin","year":"2022","journal-title":"Dermatitis"},{"key":"2023112112581886300_llad162-B43","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.anai.2019.10.005","article-title":"New treatments for atopic dermatitis targeting beyond IL-4\/IL-13 cytokines","volume":"124","author":"Renert-Yuval","year":"2020","journal-title":"Ann Allergy Asthma Immunol"},{"key":"2023112112581886300_llad162-B44","first-page":"25","article-title":"Moisturizing different racial skin types","volume":"7","author":"Wan","year":"2014","journal-title":"J Clin Aesth Dermatol"},{"key":"2023112112581886300_llad162-B45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaad.2005.01.010","article-title":"Adverse effects of topical glucocorticosteroids","volume":"54","author":"Hengge","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"2023112112581886300_llad162-B46","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.2147\/CCID.S327593","article-title":"Burden of disease, unmet needs in the diagnosis and management of atopic dermatitis: an Indian expert consensus","volume":"14","author":"Rajagopalan","year":"2021","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"2023112112581886300_llad162-B47","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1111\/j.1365-4632.2011.04881.x","article-title":"Overview of efficacy and safety of tacrolimus ointment in patients with atopic dermatitis in Asia and other areas","volume":"50","author":"Kim","year":"2011","journal-title":"Int J Dermatol"},{"issue":"Suppl. 1","key":"2023112112581886300_llad162-B48","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1067\/mjd.2001.109810","article-title":"Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: Part I, efficacy","volume":"44","author":"Hanifin","year":"2001","journal-title":"J Am Acad Dermatol"},{"key":"2023112112581886300_llad162-B49","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s40257-019-00450-w","article-title":"Efficacy and safety of crisaborole ointment, 2%, for the treatment of mild-to-moderate atopic dermatitis across racial and ethnic groups","volume":"20","author":"Callender","year":"2019","journal-title":"Am J Clin Dermatol"},{"key":"2023112112581886300_llad162-B50","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1111\/1346-8138.16120","article-title":"A phase 2b, randomized, double-blind, multicenter, vehicle-controlled study to assess the efficacy and safety of two crisaborole regimens in Japanese patients aged 2\u2005years and older with mild-to-moderate atopic dermatitis","volume":"48","author":"Fujita","year":"2021","journal-title":"J Dermatol"},{"key":"2023112112581886300_llad162-B51","doi-asserted-by":"crossref","first-page":"S99","DOI":"10.12788\/j.sder.2017.050","article-title":"Topical therapy for atopic dermatitis: new and investigational agents","volume":"36","author":"Stein Gold","year":"2017","journal-title":"Semin Cutan Med Surg"},{"key":"2023112112581886300_llad162-B52","doi-asserted-by":"crossref","first-page":"139","DOI":"10.36849\/JDD.7295","article-title":"The safety and efficacy of roflumilast cream 0.15% and 0.05% in patients with atopic dermatitis: randomized, double-blind, phase 2 proof of concept study","volume":"22","author":"Gooderham","year":"2023","journal-title":"J Drugs Dermatol"},{"key":"2023112112581886300_llad162-B53","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.jaad.2021.10.027","article-title":"Difamilast ointment in adult patients with atopic dermatitis: a phase 3 randomized, double-blind, vehicle-controlled trial","volume":"86","author":"Saeki","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"2023112112581886300_llad162-B54","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/bjd.20655","article-title":"Difamilast, a selective phosphodiesterase 4 inhibitor, ointment in paediatric patients with atopic dermatitis: a phase III randomized double-blind, vehicle-controlled trial","volume":"186","author":"Saeki","year":"2022","journal-title":"Br J Dermatol"},{"key":"2023112112581886300_llad162-B55","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14122767","article-title":"Novel therapeutic strategies in the topical treatment of atopic dermatitis","volume":"14","author":"Pinto","year":"2022","journal-title":"Pharmaceutics"},{"key":"2023112112581886300_llad162-B56","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s40257-022-00712-0","article-title":"What\u2019s new in topicals for atopic dermatitis?","volume":"23","author":"Kleinman","year":"2022","journal-title":"Am J Clin Dermatol"},{"key":"2023112112581886300_llad162-B57","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/1346-8138.15173","article-title":"Long-term safety and efficacy of delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with atopic dermatitis","volume":"47","author":"Nakagawa","year":"2020","journal-title":"J Dermatol"},{"key":"2023112112581886300_llad162-B58","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.jaad.2020.05.135","article-title":"Efficacy and patient-reported outcomes from a phase 2b, randomized clinical trial of tapinarof cream for the treatment of adolescents and adults with atopic dermatitis","volume":"84","author":"Paller","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"2023112112581886300_llad162-B59","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.sder.2011.08.007","article-title":"Role of phototherapy in patients with skin of color","volume":"30","author":"Syed","year":"2011","journal-title":"Semin Cutan Med Surg"},{"key":"2023112112581886300_llad162-B60","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1111\/pde.12405","article-title":"Is phototherapy useful in the treatment of atopic dermatitis in Asian children? A 5-year report from singapore","volume":"31","author":"Mok","year":"2014","journal-title":"Pediatr Dermatol"},{"key":"2023112112581886300_llad162-B61","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/j.1600-0781.2007.00291.x","article-title":"Phototherapy in the management of atopic dermatitis: a systematic review","volume":"23","author":"Meduri","year":"2007","journal-title":"Photodermatol Photoimmunol Photomed"},{"key":"2023112112581886300_llad162-B62","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.det.2019.08.006","article-title":"Phototherapy in skin of color","volume":"38","author":"Ware","year":"2020","journal-title":"Dermatol Clin"},{"issue":"Suppl. 3","key":"2023112112581886300_llad162-B63","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/bjd.12526","article-title":"Lasers and light-based therapies in ethnic skin: treatment options and recommendations for Fitzpatrick skin types V and VI","volume":"169","author":"Alexis","year":"2013","journal-title":"Br J Dermatol"},{"key":"2023112112581886300_llad162-B64","doi-asserted-by":"crossref","DOI":"10.1111\/dth.15047","article-title":"Feasibility of oral tranexamic acid for vitiligo patients with melasma","volume":"34","author":"Chiang","year":"2021","journal-title":"Dermatol Ther"},{"key":"2023112112581886300_llad162-B65","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/phpp.12713","article-title":"Chinese women with melasma exhibit a low minimal erythema dose to both UVA and UVB","volume":"38","author":"Wang","year":"2022","journal-title":"Photodermatol Photoimmunol Photomed"},{"key":"2023112112581886300_llad162-B66","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1111\/j.1365-2133.2008.08672.x","article-title":"UVA1 phototherapy is effective in darker skin: a review of 101 patients of Fitzpatrick skin types I\u2013V","volume":"159","author":"Jacobe","year":"2008","journal-title":"Br J Dermatol"},{"key":"2023112112581886300_llad162-B67","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s00403-006-0728-3","article-title":"Pigmentation after single and multiple UV-exposures depending on UV-spectrum","volume":"299","author":"Ravnbak","year":"2007","journal-title":"Arch Dermatol Res"},{"key":"2023112112581886300_llad162-B68","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s13555-016-0170-1","article-title":"Systemic treatment of adult atopic dermatitis: a review","volume":"7","author":"Megna","year":"2017","journal-title":"Dermatol Ther (Heidelb)"},{"key":"2023112112581886300_llad162-B69","doi-asserted-by":"crossref","first-page":"701","DOI":"10.5414\/CPP42701","article-title":"Pharmacokinetics of immunosuppressants: a perspective on ethnic differences","volume":"42","author":"Dirks","year":"2004","journal-title":"Int J Clin Pharmacol Ther"},{"key":"2023112112581886300_llad162-B70","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1067\/mcp.2000.111255","article-title":"Gender-dependent racial difference in disposition of cyclosporine among healthy African American and white volunteers","volume":"68","author":"Min","year":"2000","journal-title":"Clin Pharmacol Ther"},{"key":"2023112112581886300_llad162-B71","first-page":"114","article-title":"Evaluation of clinical efficacy and tolerability of azathioprine in adult Chinese atopic dermatitis patients in Hong Kong with pre-treatment thiopurine methyltransferase assessment","author":"Ho","year":"2013","journal-title":"Hong Kong J Dermatol Venereol"},{"key":"2023112112581886300_llad162-B72","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.jaad.2005.07.059","article-title":"Azathioprine in dermatology: the past, the present, and the future","volume":"55","author":"Patel","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"2023112112581886300_llad162-B73","first-page":"1","volume-title":"Medical Genetics Summaries","author":"Dean","year":"2012"},{"key":"2023112112581886300_llad162-B74","first-page":"3432","article-title":"The influence of race and gender on the risk of hair loss secondary to methotrexate","volume":"56","author":"Escott","year":"2015","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"2023112112581886300_llad162-B75","first-page":"572","article-title":"Methotrexate (MTX) pathway gene polymorphisms and their effects on MTX toxicity in Caucasian and African American patients with rheumatoid arthritis","volume":"35","author":"Ranganathan","year":"2008","journal-title":"J Rheumatol"},{"key":"2023112112581886300_llad162-B76","first-page":"908","article-title":"Therapeutic efficacy of mycophenolate mofetil in atopic dermatitis","volume":"40","author":"Lee","year":"2002","journal-title":"Korean J Dermatol"},{"key":"2023112112581886300_llad162-B77","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1046\/j.1365-2133.2000.03667.x","article-title":"Treatment of atopic eczema with oral mycophenolate mofetil","volume":"143","author":"Neuber","year":"2000","journal-title":"Br J Dermatol"},{"key":"2023112112581886300_llad162-B78","first-page":"804","article-title":"Efficacy of dupilumab in different racial subgroups of adults with moderate-to-severe atopic dermatitis in three randomized, placebo-controlled phase 3 trials","volume":"18","author":"Alexis","year":"2019","journal-title":"J Drugs Dermatol"},{"key":"2023112112581886300_llad162-B79","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1056\/NEJMc1700366","article-title":"Two phase 3 trials of dupilumab versus placebo in atopic dermatitis","volume":"376","author":"Simpson","year":"2017","journal-title":"N Engl J Med"},{"key":"2023112112581886300_llad162-B80","doi-asserted-by":"crossref","first-page":"297","DOI":"10.4103\/ijd.ijd_860_20","article-title":"Real-world effectiveness and safety of dupilumab for the treatment of moderate to severe atopic dermatitis in Indian patients: a multi centric retrospective study","volume":"66","author":"Dhar","year":"2021","journal-title":"Indian J Dermatol"},{"key":"2023112112581886300_llad162-B81","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/bjd.19574","article-title":"Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2)","volume":"184","author":"Wollenberg","year":"2021","journal-title":"Br J Dermatol"},{"key":"2023112112581886300_llad162-B82","doi-asserted-by":"crossref","first-page":"14293","DOI":"10.1038\/s41598-021-93750-3","article-title":"Ocular surface disorders associated with the use of dupilumab based on WHO VigiBase","volume":"11","author":"Park","year":"2021","journal-title":"Sci Rep"},{"key":"2023112112581886300_llad162-B83","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1136\/bjo.87.9.1195-a","article-title":"Demographic study of paediatric allergic conjunctivitis within a multiethnic patient population","volume":"87","author":"Singh","year":"2003","journal-title":"Br J Ophthalmol"},{"key":"2023112112581886300_llad162-B84","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.alit.2020.06.004","article-title":"Epidemiological aspects of allergic conjunctivitis","volume":"69","author":"Miyazaki","year":"2020","journal-title":"Allergol Inter"},{"key":"2023112112581886300_llad162-B85","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1111\/bjd.20690","article-title":"The efficacy and safety of dupilumab in Chinese patients with moderate-to-severe atopic dermatitis: a randomized, double-blind, placebo-controlled study","volume":"186","author":"Zhao","year":"2022","journal-title":"Br J Dermatol"},{"key":"2023112112581886300_llad162-B86","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1111\/jdv.18109","article-title":"Real-world efficacy and safety of dupilumab in Chinese patients with atopic dermatitis: a single-centre, prospective, open-label study","volume":"36","author":"Gu","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2023112112581886300_llad162-B87","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1001\/jamadermatol.2020.0079","article-title":"Efficacy and safety of lebrikizumab, a high-affinity interleukin 13 inhibitor, in adults with moderate to severe atopic dermatitis: a phase 2b randomized clinical trial","volume":"156","author":"Guttman-Yassky","year":"2020","journal-title":"JAMA Dermatol"},{"key":"2023112112581886300_llad162-B88","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.jaad.2018.01.017","article-title":"Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: a randomized, placebo-controlled phase II trial (TREBLE)","volume":"78","author":"Simpson","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"2023112112581886300_llad162-B89","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1038\/jid.2008.111","article-title":"Possible pathogenic role of Th17 cells for atopic dermatitis","volume":"128","author":"Koga","year":"2008","journal-title":"J Invest Dermatol"},{"key":"2023112112581886300_llad162-B90","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaci.2018.10.032","article-title":"Atopic dermatitis endotypes and implications for targeted therapeutics","volume":"143","author":"Czarnowicki","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"2023112112581886300_llad162-B91","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1111\/bjd.15493","article-title":"Efficacy and safety of ustekinumab in Japanese patients with severe atopic dermatitis: a randomized, double-blind, placebo-controlled, phase II study","volume":"177","author":"Saeki","year":"2017","journal-title":"Br J Dermatol"},{"key":"2023112112581886300_llad162-B92","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.jaci.2020.04.055","article-title":"Phase 2 randomized, double-blind study of IL-17 targeting with secukinumab in atopic dermatitis","volume":"147","author":"Ungar","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"2023112112581886300_llad162-B93","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.jaad.2018.01.016","article-title":"Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: a randomized, double-blind, phase 2a trial","volume":"78","author":"Guttman-Yassky","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"2023112112581886300_llad162-B94","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1056\/NEJMoa1917006","article-title":"Trial of nemolizumab and topical agents for atopic dermatitis with pruritus","volume":"383","author":"Kabashima","year":"2020","journal-title":"N Engl J Med"},{"key":"2023112112581886300_llad162-B95","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1111\/jdv.17218","article-title":"Nemolizumab is associated with a rapid improvement in atopic dermatitis signs and symptoms: subpopulation (EASI \u2265 16) analysis of randomized phase 2B study","volume":"35","author":"Silverberg","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2023112112581886300_llad162-B96","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1159\/000518541","article-title":"Efficacy and safety of Janus kinase inhibitors for the treatment of atopic dermatitis: a systematic review and meta-analysis","volume":"238","author":"Li","year":"2022","journal-title":"Dermatology"},{"key":"2023112112581886300_llad162-B97","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1111\/ced.14567","article-title":"Janus kinase inhibitors for atopic dermatitis: a promising treatment modality","volume":"46","author":"Cartron","year":"2021","journal-title":"Clin Exp Dermatol"},{"key":"2023112112581886300_llad162-B98","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/s40257-021-00618-3","article-title":"Integrated safety analysis of abrocitinib for the treatment of moderate-to-severe atopic dermatitis from the phase II and phase III clinical trial program","volume":"22","author":"Simpson","year":"2021","journal-title":"Am J Clin Dermatol"},{"key":"2023112112581886300_llad162-B99","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.alit.2021.10.004","article-title":"Innovation in the treatment of atopic dermatitis: emerging topical and oral Janus kinase inhibitors","volume":"71","author":"Nakashima","year":"2022","journal-title":"Allergol Int"},{"key":"2023112112581886300_llad162-B100","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1007\/s40257-021-00627-2","article-title":"Efficacy and safety of SHR0302, a highly selective Janus kinase 1 inhibitor, in patients with moderate to severe atopic dermatitis: a phase II randomized clinical trial","volume":"22","author":"Zhao","year":"2021","journal-title":"Am J Clin Dermatol"},{"key":"2023112112581886300_llad162-B101","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s40264-021-01067-x","article-title":"The safety profile of upadacitinib in patients with rheumatoid arthritis in Japan","volume":"44","author":"Yamaoka","year":"2021","journal-title":"Drug Saf"},{"key":"2023112112581886300_llad162-B102","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1111\/1756-185X.14235","article-title":"Upadacitinib in patients from China, Brazil, and South Korea with rheumatoid arthritis and an inadequate response to conventional therapy","volume":"24","author":"Zeng","year":"2021","journal-title":"Int J Rheumat Dis"},{"key":"2023112112581886300_llad162-B103","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1001\/jamadermatol.2022.0029","article-title":"Efficacy and safety of upadacitinib in patients with moderate to severe atopic dermatitis: analysis of follow-up data from the measure up 1 and measure up 2 randomized clinical trials","volume":"158","author":"Simpson","year":"2022","journal-title":"JAMA Dermatol"}],"container-title":["Clinical and Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ced\/advance-article-pdf\/doi\/10.1093\/ced\/llad162\/50887335\/llad162.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/48\/10\/1091\/53664905\/llad162.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/48\/10\/1091\/53664905\/llad162.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,19]],"date-time":"2024-10-19T09:45:09Z","timestamp":1729331109000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ced\/article\/48\/10\/1091\/7147058"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,29]]},"references-count":103,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2023,4,29]]},"published-print":{"date-parts":[[2023,9,19]]}},"URL":"https:\/\/doi.org\/10.1093\/ced\/llad162","relation":{},"ISSN":["0307-6938","1365-2230"],"issn-type":[{"value":"0307-6938","type":"print"},{"value":"1365-2230","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,10]]},"published":{"date-parts":[[2023,4,29]]}}}